FindTrial
Sign In

Establishment of Traditional Chinese Medicine pattern and immune classification of allergic rhinitis caused by Artemisia pollen in northern China and their application in predicting the efficacy of allergen immunotherapy

Construction and promotion of a system for hay fever precise diagnosis and treatment in Inner Mongolia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126258
Enrollment
Unknown
Registered
2026-06-05
Start date
2026-04-20
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

Desensitization treatment allergic rhinitis group:None
Allergic Rhinitis group:None
Health Control:None

Sponsors

Hohhot First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of "Chinese Guidelines for the diagnosis and treatment of allergic Rhinitis (2025 version)", artemisia annua sensitization (SPT >=+++ or artemisia annua sIgE >=0.35kUA/L, no other allergen allergy); 2. Holding a positive report of skin prick test for Artemisia within the past 2 years; 3, age 4-60 years old, both sexes; 4. Voluntarily accept SLIT treatment with standard artemisia annua allergen, and can cooperate to complete 3-year follow-up and various tests; 5. No use of systemic glucocorticoids, antihistamines and other immunomodulatory/symptomatic drugs in the past 1 month; 6. received the first artemisia annua desensitization treatment.

Exclusion criteria

Exclusion criteria: 1. Combined with moderate to severe bronchial asthma, chronic rhinosinusitis with nasal polyps and other respiratory diseases; 2. Combined with autoimmune diseases, malignant tumors, immunodeficiency diseases, etc. 3. severe or controlled asthma (FEVI < 70% predicted value), irreversible obstructive respiratory diseases; 4. Pregnant/lactating women; 5. A history of infection or surgery in the past 3 months, or long-term use of immunosuppressants; 6. Allergic to the ingredients of artemisia annua allergen preparation.

Design outcomes

Primary

MeasureTime frame
Symptom scores based on a quadrangular scale and therapeutic effectiveness;—

Secondary

MeasureTime frame
Symptom score based on Visual Analogue Scale (VAS);Total medication scores, TMS;Total Serum IgE;Routine blood tests;Peripheral blood cytokine;Nasal microbes;Feca and serum metapolites;Artemisia specific IgE;Artemisia specific IgG4;B cell subsets;Olink immunophenotyping;chinese medicine symptom;—

Countries

China

Contacts

Public ContactJunjing Zhang

Hohhot First Hospital

Zhang.jj@vip.163.com+86 135 0069 6309

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026